两例EDTA依赖性假性血小板减少应用阿米卡星无效探讨

目的探讨2例乙二胺四乙酸(EDTA)依赖性假性血小板减少应用阿米卡星无效的机制。方法对2例EDTA依赖性假性血小板减少症患者的EDTA-K2抗凝血,在不同时间段分别加入阿米卡星,在血液分析仪检测,血涂片检查。结果该2名患者,加或不加阿米卡星,其血小板数均会随着时间的延长逐渐增加,其特征性的直方图也会随着时间的延长而消失,加入阿米卡星会获得更可靠的结果。结论阿米卡星并不能立即解离2例患者聚集的血小板,但随着时间延长,血小板缓慢解离,至4h达到相对稳定。1h内加入阿米卡星较为理想,相对普通EDTA抗凝可有效加速其解离过程,获得理想结果。     

肺隐球菌病1例报告并国内文献复习

目的：了解肺隐球菌病的发病特点，提高认识水平。方法：报告1例肺隐球菌病患者的临床资料，并通过检索中国医院数字图书馆系统，复习了60篇相关文献，总结其临床表现、影像学特点、诊断方法及治疗手段。结果：肺隐球菌病的临床表现无特异，影像学改变因患者的免疫功能不同而有差异，诊断依赖病理学，治疗尚存在争议。结论：肺隐球菌病的发病率逐年增高，应当受到重视，以提高诊断准确性。     

The role of NK cells in fighting the virus infection and sepsis

Natural killer cells, one of the important types of innate immune cells, play a pivotal role in the antiviral process in vivo. It has been shown that increasing NK cell activity may promote the alleviation of viral infections, even severe infection-induced sepsis. Given the current state of the novel coronavirus (SARS-CoV-2) global pandemic, clarifying the anti-viral function of NK cells would be helpful for revealing the mechanism of host immune responses and decipher the progression of COVID-19 and providing important clues for combating this pandemic. In this review, we summarize the roles of NK cells in viral infection and sepsis as well as the potential possibilities of NK cell-based immunotherapy for treating COVID-19.     

Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease

Introduction

The prognosis of anti-MDA5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis-associated interstitial lung disease (MDA5-DM/CADM-ILD) is poor. This study was to evaluate the effect of serum soluble CD206 (sCD206), a biomarker of macrophage activation, on predicting the interstitial lung disease (ILD) deterioration and prognosis for MDA5-DM/CADM-ILD.

Methods

Forty-one patients diagnosed with MDA5-DM/CADM-ILD were retrospectively included. The clinical data were analyzed. Serum sCD206 levels were measured in 41 patients and 30 healthy controls. The relation between sCD206 levels and ILD deterioration was assessed. Receiver operating characteristic (ROC) curve was generated to determine the optimal cut-off value of sCD206 for predicting outcome. The association between sCD206 and survival was examined.

Results

The median serum sCD206 level in patients was significantly higher than healthy controls (464.1 ng/mL vs. 349.1 ng/mL, P = 0.002). In DM/CADM patients, the sCD206 level was significantly higher in patients with acute/subacute interstitial lung disease (AILD/SILD) than those with chronic interstitial lung disease (CILD) (539.2 ng/mL vs. 309.4 ng/mL, P = 0.005). The AUC of sCD206 was 0.885 for predicting mortality (95% CI 0.779–0.990). Patients were divided into two groups: sCD206 high level group (≥400 ng/mL) and sCD206 low level group (<400 ng/mL). Patients with sCD206 high level had significantly decreased survival rate than those with low level (25% vs. 88%, P < 0.001). The adjusted hazard ratio of sCD206 for mortality was 1.003 (adjusted for age and gender, P < 0.001), with sCD206 high level associated with higher death risk (HR 4.857, P = 0.006).

Conclusion

Serum sCD206 might be a potential predictor of ILD deterioration and prognosis for Chinese patients with MDA5-DM/CADM-ILD.     

生命体中的超氧化物歧化酶(综述)

超氧化物歧化酶(SOD)是生物体内清除超氧阴离子自由基的一种重要酶,它能有效地使机体抗御氧自由基的毒性.文章中综述了SOD的来源、分布、种类、结构性质制备、活性测定、化学修饰,以及在临床、食品、化妆品等方面的应用.     

多项指标联合检测对急性心肌梗死患者心源性死亡的预测价值

急性心肌梗死(AMI)易导致心源性死亡,早期准确识别出AMI中的高危患者,才能有针对性地选择治疗和预防措施。本文通过观察AMI患者心率震荡(HRT)的震荡起始(TO)与震荡斜率(TS)指标、心率变异性(HRV)的时域指标(SDNN)与心率变异三角指数(HRVTI),以及常规超声心动图,包括左房舒张末期前后径(LAED)、左室舒张末期前后径(LVED)、左室射血分数(LVEF)和短轴缩短率(LVFS)等指标,以探讨对AMI患者心源性死亡具有较高预测价值的指标与方法。1对象与方法     

Ethyl Pyruvate Alleviates Pulmonary Hypertension through the Suppression of Pulmonary Artery Smooth Muscle Cell Proliferation via the High Mobility Group Protein B1/Receptor for Advanced Glycation End-Products Axis

Purpose: Pulmonary arterial hypertension (PAH) is a formidable disease with no effective treatment at present. With the goal of developing potential therapies, we attempted to determine whether ethyl pyruvate (EP) could alleviate PAH and its mechanism.Methods: Pulmonary smooth muscle cells were cultured in conventional low-oxygen environments, and cellular proliferation was monitored after treatment with either EP or phosphate-balanced solution (PBS). Expression of high mobility group protein B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) protein were detected by western blot. After hyperkinetic PAH rat models were treated with EP, hemodynamic data were collected. Right ventricular hypertrophy and pulmonary vascular remodeling were evaluated. Expression of HMGB1 and RAGE protein was also detected.Results: In vitro, proliferative activity increased in low-oxygen environments, but was inhibited by EP treatment. Furthermore, Western blotting showed the decreased expression of HMGB1 and RAGE protein after EP treatment. In vivo, pulmonary artery pressures were attenuated with EP. Right ventricular hypertrophy and pulmonary vascular remodeling were also reversed. Additionally, the expression levels of HMGB1 and RAGE were reduced in lung tissues.Conclusions: EP can alleviate PAH by suppressing the proliferation of pulmonary artery smooth muscle cells via inhibition of HMGB1/RAGE expression.